These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26285165)

  • 1. Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
    Kim HN; Kim YR; Ahn SM; Lee SK; Shin HK; Choi BT
    J Neurochem; 2015 Nov; 135(3):577-88. PubMed ID: 26285165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
    Hu X; Qin X
    Int J Mol Med; 2013 May; 31(5):1209-21. PubMed ID: 23525227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal Stem Cells Attenuated Blood-Brain Barrier Disruption via Downregulation of Aquaporin-4 Expression in EAE Mice.
    Liu Y; Ma Y; Du B; Wang Y; Yang GY; Bi X
    Mol Neurobiol; 2020 Sep; 57(9):3891-3901. PubMed ID: 32613467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol defends blood-brain barrier integrity in experimental autoimmune encephalomyelitis mice.
    Wang D; Li SP; Fu JS; Zhang S; Bai L; Guo L
    J Neurophysiol; 2016 Nov; 116(5):2173-2179. PubMed ID: 27535376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE.
    Bennett J; Basivireddy J; Kollar A; Biron KE; Reickmann P; Jefferies WA; McQuaid S
    J Neuroimmunol; 2010 Dec; 229(1-2):180-91. PubMed ID: 20832870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idazoxan reduces blood-brain barrier damage during experimental autoimmune encephalomyelitis in mouse.
    Wang XS; Fang HL; Chen Y; Liang SS; Zhu ZG; Zeng QY; Li J; Xu HQ; Shao B; He JC; Hou ST; Zheng RY
    Eur J Pharmacol; 2014 Aug; 736():70-6. PubMed ID: 24797785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis.
    Errede M; Girolamo F; Ferrara G; Strippoli M; Morando S; Boldrin V; Rizzi M; Uccelli A; Perris R; Bendotti C; Salmona M; Roncali L; Virgintino D
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):840-54. PubMed ID: 23001217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis.
    Lanz TV; Becker S; Osswald M; Bittner S; Schuhmann MK; Opitz CA; Gaikwad S; Wiestler B; Litzenburger UM; Sahm F; Ott M; Iwantscheff S; Grabitz C; Mittelbronn M; von Deimling A; Winkler F; Meuth SG; Wick W; Platten M
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14735-40. PubMed ID: 23959874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial α6β4 integrin protects during experimental autoimmune encephalomyelitis-induced neuroinflammation by maintaining vascular integrity and tight junction protein expression.
    Welser JV; Halder SK; Kant R; Boroujerdi A; Milner R
    J Neuroinflammation; 2017 Nov; 14(1):217. PubMed ID: 29121970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction.
    Prasad R; Giri S; Nath N; Singh I; Singh AK
    J Neurosci Res; 2006 Aug; 84(3):614-25. PubMed ID: 16770773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-inflammatory effect of donepezil on experimental autoimmune encephalomyelitis in C57 BL/6 mice.
    Jiang Y; Zou Y; Chen S; Zhu C; Wu A; Liu Y; Ma L; Zhu D; Ma X; Liu M; Kang Z; Pi R; Peng F; Wang Q; Chen X
    Neuropharmacology; 2013 Oct; 73():415-24. PubMed ID: 23831366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
    Bénardais K; Pul R; Singh V; Skripuletz T; Lee DH; Linker RA; Gudi V; Stangel M
    Neurosci Lett; 2013 Oct; 555():165-70. PubMed ID: 24076006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
    Göbel K; Pankratz S; Schneider-Hohendorf T; Bittner S; Schuhmann MK; Langer HF; Stoll G; Wiendl H; Kleinschnitz C; Meuth SG
    J Autoimmun; 2011 Mar; 36(2):106-14. PubMed ID: 21216565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions.
    Chapouly C; Tadesse Argaw A; Horng S; Castro K; Zhang J; Asp L; Loo H; Laitman BM; Mariani JN; Straus Farber R; Zaslavsky E; Nudelman G; Raine CS; John GR
    Brain; 2015 Jun; 138(Pt 6):1548-67. PubMed ID: 25805644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of kinin B1 and B2 receptors in the persistent pain induced by experimental autoimmune encephalomyelitis (EAE) in mice: evidence for the involvement of astrocytes.
    Dutra RC; Bento AF; Leite DF; Manjavachi MN; Marcon R; Bicca MA; Pesquero JB; Calixto JB
    Neurobiol Dis; 2013 Jun; 54():82-93. PubMed ID: 23454198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice.
    Thorne M; Moore CS; Robertson GS
    J Neuroimmunol; 2009 Jun; 211(1-2):92-100. PubMed ID: 19428125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular mechanisms of IL-17-induced blood-brain barrier disruption.
    Huppert J; Closhen D; Croxford A; White R; Kulig P; Pietrowski E; Bechmann I; Becher B; Luhmann HJ; Waisman A; Kuhlmann CR
    FASEB J; 2010 Apr; 24(4):1023-34. PubMed ID: 19940258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood-brain barrier and blood-cerebrospinal fluid barrier.
    Wang C; Wang C; Dong H; Wu XM; Wang C; Xia F; Li G; Jia X; He S; Jiang X; Li H; Xu H
    Mol Immunol; 2013 Jan; 53(1-2):43-51. PubMed ID: 22796503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism.
    Wang T; Xi NN; Chen Y; Shang XF; Hu Q; Chen JF; Zheng RY
    Neuropharmacology; 2014 Nov; 86():203-11. PubMed ID: 25019206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.